Harris Williams & Co. Advises EAG Laboratories on its Sale to Eurofins Scientific for $780 Million
Harris Williams & Co., a preeminent middle market investment bank focused on the advisory needs of clients worldwide for more than 25 years, announces that it advised EAG Laboratories (EAG), a portfolio company of a fund managed by Odyssey Investment Partners, LLC (Odyssey), on its sale to Eurofins Scientific (Paris: ERF; Eurofins) for $780 million. EAG is a leading global scientific services company providing analytical testing and consulting services to a diverse and demanding set of end markets. The transaction was led by Brian Lucas, Luke Semple and Ian Thomas of Harris Williams & Co.’s Richmond office.
EAG, headquartered in San Diego, has 21 laboratories in 18 locations worldwide, serving approximately 4,000 customers with revenue generated from more than 50 countries. The company is one of the largest independent U.S.-centric platforms in the TIC market and is a highly differentiated player in high-science analytical testing and consulting solutions. EAG serves three main markets, namely material and engineering sciences, agroscience and biopharmaceuticals.
Odyssey, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 20 year history of partnering with skilled managers to transform middle market companies into more efficient and diversified business with strong growth profiles. Odyssey makes majority controlled investments in industries with a long-term positive outlook and favorable secular trends.
Eurofins is a leader in food, environment and pharmaceutical products testing and is one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the U.S. With over 30,000 staff in 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic.
Harris Williams & Co. (www.harriswilliams.com), a subsidiary of the PNC Financial Services Group, Inc. (NYSE:PNC), is a preeminent middle market investment bank focused on the advisory needs of clients worldwide. The firm has deep industry knowledge, global transaction expertise, and an unwavering commitment to excellence. Harris Williams & Co. provides sell-side and acquisition advisory, restructuring advisory, board advisory, private placements, and capital markets advisory services.
Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which is a private limited company incorporated under English law with its registered office at 5th Floor, 6 St. Andrew Street, London EC4A 3AE, UK, registered with the Registrar of Companies for England and Wales (registration number 7078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. is a trade name under which Harris Williams LLC and Harris Williams & Co. Ltd conduct business.